Blood test could replace bone scans for osteoporosis monitoring

NCT ID NCT07242612

Completed Knowledge-focused Sponsor: Khyber Medical University Peshawar Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Aug 14, 2026 · Updated 4 times

Summary

This study looks at whether blood tests called bone turnover markers can quickly show if osteoporosis drugs are working in postmenopausal women. Forty women will receive either bone-strengthening or bone-building medications for six months. The goal is to see if these blood tests can replace slow DEXA scans, especially in places with limited access to scanners.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Alendronate, Ibandronate, Risedronate, or Teriparatide
What this could lead to: If successful, this could show that simple blood tests can quickly tell if osteoporosis treatment is working, making monitoring easier in areas without advanced scanners.
What could go wrong: This is a small, early study with only 40 participants, so results may not apply to everyone. The blood tests might not reliably predict bone strength or fracture risk.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for OSTEOPOROSIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

osteoporosis postmenopausal osteoporosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

OSTEOPOROSIS OSTEOPOROSIS, POSTMENOPAUSAL

Contacts and locations

Locations

Northwest General Hospital

Peshawar, Khyber Pakhtunkhwa, 25000, Pakistan

More trials for these conditions

Other studies related to the condition(s) this trial covers.